The new opportunities of treatment of non-alcoholic steatohepatitis
Journal Title: Сучасна гастроентерологія - Year 2018, Vol 0, Issue 1
Abstract
Objective — to evaluate the efficacy and safety of the dietary supplement Schisandrin®, 250 mg tablets (manufacturer Pharmacom Ltd.) in patients with non-alcoholic steatohepatitis. Materials and methods. The investigation involved 40 patients (18 (45 %) men and 22 (55 %) women) with non-alcoholic steatohepatitis (NASH), aged 25 to 65 years old (the mean age 43.6 ± 11.3 years). The control group consisted of 10 healthy subjects. Clinical examinations included assessment of data of anthropometric measuring, blood pressure, determination of serum levels of C-reactive protein (CRP) and TNF-alpha in serum, degree of liver steatosis. The treatment was performed with the drug Schisandrin® for 12 weeks in different dosage regimens: I group — 20 patients receiving the drug Schisandrin® 1 tablet 3 times a day; II group — 20 patients who received the drug Schisandrin® for 2 tablets 3 times a day. Results. In the course of treatment, there was a significant dynamics of the main clinical manifestations, i.e. symptoms’ removal or relief, which more rapidly and substantially reduced in patients of group II, as well as decreased activity of the inflammatory process in the liver tissue. The intake of Schisandrin® significantly reduced the increased ALT and AST activity and level of cholestasis markers in patients with NASH, this effect was dose-dependent, too. By the end of third months of therapy, a decrease in the level of high-sensitivity CRP and serum TNF-α levels in the examined patients was achieved, more substantial changes were observed in patients of group II. The improvement of ultrasound characteristics has been revealed, including tendency towards normalization of the acoustic density and liver size due reduction of steatosis degree. Conclusions. It has been demonstrated that Schisandrin® had a positive effects on the NASH course, with a higher efficacy and dose-dependent effects in the treatment regimen of 2 tablets 3 times a day for 3 months. This dose proved to be highly safe and well tolerated. Schisandrin® can serve as an alternative to the treatment of patients with non-alcoholic fatty liver disease at the NASH stage, not only in the stage of activation of the inflammatory process in the liver tissue, but also at the stage of supportive therapy in order to prevent the disease progression.
Authors and Affiliations
G. D. Fadieienko, O. V. Kolesnikova, T. A. Solomenseva
Keywords
Related Articles
- EP ID EP276249
- DOI -
- Views 136
- Downloads 0
The role of thyroid hormones in the formation mechanisms of motor-secretory disorders in patients with gastroesophageal reflux disease with concomitant autoimmune thyroiditis
Objective — to study the role of thyroid hormones in the formation of motor-secretory disorders with the comorbid course of gastroesophageal reflux disease (GERD) and autoimmune thyroiditis (AIT). Materials and methods....
The rational choice of drugs for the dyspepsia treatment in an outpatient clinic
Objective — to conduct a comparative evaluation of the clinical efficacy of pantoprazole, aluminium phosphate gel and drotaverine in the treatment of patients with dyspepsia. Materials and methods. The open comparative...
NSAID-enterotoxicity: focus on the problem
The nonsteroidal anti-inflammatory drugs (NSAIDs) are the most commonly prescribed medicines in the world. They are almost indispensable for quick elimination of pain, inflammation, and hyperthermia, but unfortunately, t...
The role of intestinal microbiome in the progression of non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is considered an important and economically significant public health problem, its progression can result in development of cirrhosis and hepatocellular carcinoma. Over the past...
The role of proton pump inhibitors in the treatment of chronic pancreatitis. Review and own observation
The article presents analysis of the literature data on the role of acid-producing gastric function in pancreatic secretion. The indications for prescribing the proton pump inhibitors upon chronic pancreatitis are explai...